![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 28, 21525-21531, July 14, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,From the First Department of Pathology, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan
Received for publication, December 6, 1999, and in revised form, April 11, 2000
| |
ABSTRACT |
|---|
|
|
|---|
A novel protein kinase, TOPK (T-LAK
cell-originated protein kinase), was isolated from a
lymphokine-activated killer T (T-LAK) cell subtraction cDNA
fragment library. The open reading frame of the TOPK gene
encodes a protein of 322 amino acids, possessing a protein kinase
domain profile. The cap site analysis of the 5'-end of TOPK mRNA
revealed two forms, a major full-length form and a minor spliced form
at the 5'-site, both encoding the same protein. A BLAST homology search
and phylogenetic analysis indicated that TOPK is related to dual
specific mitogen-activated protein kinase kinase (MAPKK). The
transfection of the TOPK gene to COS-7 cells up-regulated a
phosphorylation of p38 MAPK but not ERK1/2 or SAPK/JNK. Gel
precipitation study indicated that TOPK protein can be associated with
p38 in vitro. Tissue distribution of TOPK mRNA
expression was specific for the testis, T-LAK cells, activated lymphoid
cells, and lymphoid tumors. On the other hand, deactivated T-LAK cells
did not show TOPK mRNA expression. These data suggest that TOPK is
a newly identified member of a novel MEK3/6-related MAPKK that may be
enrolled in the activation of lymphoid cells and support testicular functions.
Numerous protein kinases have been identified as cellular
components that mediate various types of intracellular signaling in
response to extracellular stimulation and intracellular homeostatic events (1, 2). While tyrosine-specific kinases are taking part in the
membrane receptor-associated signals in many instances, the counterpart
of kinases, serine/threonine-specific kinases with or without tyrosine
or dual specificity, also play important roles in the nonreceptor-type
intracellular signaling, as in the case, for example, of
mitogen-activated protein kinases
(MAPKs)1 and
cyclin-dependent kinases (3, 4). Making abundant
subfamilies and threads, both tyrosine and serine/threonine kinases are
functionally active in maintaining cellular functions and homeostasis.
The mitogen-activated protein kinase cascade conducts many biological
actions in cells (2, 5). Three subfamilies of MAPK have been
identified: p38 kinases, c-Jun N-terminal kinases (JNK), and
extracellular signal-regulated kinases (ERK). In immune cells, p38 MAPK
has an important role in mediating activation- and
proliferation-related functions in vitro. Signaling through the T-cell receptor complex and CD28 are mediated by the
phosphorylation of p38 (6, 7, 8), which in turn phosphorylates a series of kinases and nuclear transcription factors such as MAPK activated protein and C-EBP homologous protein. The cytokine production of
lymphocytes and macrophages is stimulated by the phosphorylation of p38
but not JNK or ERK (7, 9, 10). The signaling through CD40 is also
mediated by p38 (11).
Lymphokine-activated killer T (T-LAK) cells possess cytotoxic functions
against cancer cells (12, 13). They are mainly composed of activated
T-lymphocytes. T-LAK cells express the membrane-associated lymphotoxin,
a complex of soluble lymphotoxin- The T-LAK Cell Subtraction Library--
T-LAK cell cDNA
subtraction fragment library was prepared using a PCR-based method
(18). In brief, peripheral blood mononuclear cells were separated from
a healthy donor using heparinization by a discontinuous density
gradient centrifugation with Ficoll-Conray (specific gravity, 1.077).
Peripheral blood mononuclear cells were cultivated with RPMI 1640 medium supplemented with 10% fetal bovine serum (10% RPMI), 400 IU/ml
interleukin-2 (LAK media), and 0.4 µg/ml phytohemagglutinin at
37 °C, 5% CO2. On the 4th day of culturing, cells were
passaged with LAK media at a cell concentration of 0.5 × 106/ml and then passaged every 2 days using LAK media.
After 7 days of culturing, cells were used for experiments as T-LAK
cells (that is, as membrane lymphotoxin (mLT)-positive T-LAK cells
because of the expression of mLT on the cell surface). The phenotypic expression of CD3 antigen on T-LAK cells was >95%. For the
establishment of a deactivated form of T-LAK cells (mLT-negative T-LAK
cells), cells were washed twice with phosphate-buffered saline (PBS)
and cultured with 10% RPMI without interleukin-2 for 18-24 h at
37 °C, 5% CO2. The differences in the activities and
phenotypic expressions between activated and deactivated T-LAK cells
were reported previously. To summarize those differences, the
phenotypic expression such as CD3, CD4, and CD8 and the cytotoxic
activity of these two cells are not significantly different, whereas
the cytolytic activity, i.e. the cytotoxic activity based on
cytokine production, of the deactivated form is considerably lower than
that of the activated form (16, 17). The mRNA were separated from
both types of T-LAK cells, and the double stranded cDNA was
prepared using kits (Amersham Pharmacia Biotech). After digestion of
double stranded cDNA by Sau3AI (Toyobo, Tokyo, Japan) at
37 °C for 3 h, cDNA fragments of both activated (sense) and
deactivated (subtractor) T-LAK cells were ligated with an R-primer set
(R-Bgl 24: 5'-AGCACTCTCCAGCCTCTCACGGCA-3'; R-BglI2:5'-GATCTGCGGTGA-3') at both ends using T4 DNA ligase
(Toyobo) after annealing these two primers. The primers were amplified by PCR using AmpliTaq (Applied Biosystems, Urayasu, Japan) and R-Bgl 24 primer. The PCR products were digested by Sau3AI, and the
sense fragments were then ligated with a J-primer set (J-Bgl 24:
5'-ACCGACGTCGACTATCCATGAACA-3'; J-BglI2:
5'-GATCTGTTCATG-3') using T4 DNA ligase after primer annealing.
The sense fragment ligated with J-primer sets was mixed with an
excess amount of subtractor fragments, and the mixture was heated to
94 °C for 90 s followed by annealing at 67 °C for 20 h.
The mixture was amplified by PCR using J-Bgl 24 primer (PCR
subtraction), and the product was then digested by Sau3AI
again. After the removal of digested small fragments, sense fragments
were ligated with an N-primer set (N-Bgl 24:
5'-AGGCAACTGTGCTATCCGAGGGAA-3'; N-BglI2: 5'-GATCTTCCCTCG-3')
using T4 ligase at both ends, and a PCR-based subtraction was carried
out using N-Bgl 24 primer and the excess amount of subtractor
fragments. The final PCR product was cloned using a pGEM-T cloning
system (Promega, Tokyo, Japan), and it was submitted as a T-LAK
subtraction library after the transformation of JM109 Escherichia
coli cells. Random sequencing of the library was carried out, and
data were analyzed by the BLAST homology search on the Baylor College
of Medicine search launcher page or on the Genome Net search launcher
page. Consensus cDNA fragments encoding a serine/threonine kinase
were identified.
Cloning of TOPK--
Cloning of TOPK was carried out using the
Rapid Screen cDNA library panel kit of the human spleen (Origene
Technologies Inc., Rockville, MD). In brief, a master plate of the
human spleen origin was screened by a PCR method using a specific
primer set (N2H1F1: 5'-GCCAGCCAAGATCCTTTTCC-3' and N2H1B1:
5'-AGTTCCCAACGCTGCATAGTATG-3") designed from the above-mentioned
cDNA fragment. Positive wells were selected, and the subplates
responsible for each positive well were screened by PCR using the same
primers. The colonies in the positive wells in subplates were then
screened by PCR again, and positive clones were selected and recloning
was carried out. The plasmid vector employed in this library system was
pCMV6-XL3. Two clones were obtained (N2H1#1 and N2H1#2). Sequencing
analysis was carried out using a genetic analyzer (model 310; Applied
Biosystems) with a Big Dye terminator system (Applied Biosystems) and
specific sequencing primers.
Cap Site Analysis of TOPK--
Transcriptional initiating point
analysis based on the capping structure of mRNA was carried out
using a cap site cDNA human spleen kit (Nippon Gene, Tokyo, Japan)
(19). Two reverse primers of human TOPK in the cloned 5'-cDNA
region were designed (N2H1Cap1: 5'-CTTCAAAATTGGTCCCGAG-3'; N2H1Cap2:
5'-TAGCACCAACACATACGCCC-3'). The first PCR was carried out using
N2H1Cap1 and CR1 kit primers with the kit template. The second PCR was
then carried out using N2H1Cap2 and CR2 kit primers with the first PCR
product as the template. The second PCR product was analyzed by an
agarose gel electrophoresis, purified using the NucleoSpin Extract kit
(Sawady, Tokyo, Japan) and cloned using a T-vector system (Promega,
Madison, WI). The clones obtained by this method were subjected to the sequencing analysis using the 310 genetic analyzer.
Recombinant Proteins and Expression Analysis--
A PCR-based
cloning for the recombinant TOPK protein was carried out using pGEX-2TK
and specific primers. PCR was carried out using specific primers
(N2H1recF1-BamHI:
5'-TACGGGATCCGCTTTCACAATGGAAGGGATCAG-3'; N2H1recB1-EcoRI: 5'-TCCGGAATTCTTACGCAAGCCACACTTCAGC-3'),
AmpliTaq polymerase, and a purified plasmid of N2H1#1 as a template.
The PCR product and pGEX-2TK were digested by BamHI (Life
Technologies, Inc., Rockville, MD) and EcoRI (Life
Technologies, Inc.) and ligated using T4 ligase. Transformation was
carried out using DH10B E. coli cells and an electroporator
(Electro Cell Manipulator 600; BTX, Tokyo, Japan). Several colonies
were picked up, and sequencing analyses were carried out. One clone
(pGEX-TOPK) was finally selected, and a transformation of BL21(DE3) was
carried out using chemically competent cells. The GST-TOPK fusion
protein was induced by the addition of 0.1 mM
isopropyl-1-thio-
The TOPK vector for the transfection analysis of cultured cells was
elaborated using pcDNA3-MRGS-His6-Tag vector and the digested insert of pGEX-TOPK by BamHI and EcoRI. The
ligated product was used for the transformation of DH10B E. coli cells by an electroporation method, and a clone was finally
selected (pcDNA3RGS-TOPK). The p38 expression vector was prepared
by a ligation of PCR product using specific primers
(Rec-p38F-BamHI: GCCGGATCCATGTCTCAGGAGAGGCCCAC and
Rec-p38B-BamHI: GCCGGATCCTCAGGACTCCATCTCTTCTT) and
mLT2+ LAK cDNA as a template. After digestion of the
PCR product and pcDNA3 vector by BamHI, fragments were
ligated and the transformation of E. coli was carried out as
described above. The sequence of the selected clone was confirmed using
the 310 genetic analyzer.
Plasmid was purified using a Maxi prep kit (Quiagen, Tokyo, Japan).
Transfection of COS-7 cells was carried out using Lipofect AMINE (Life
Technologies, Inc.). In brief, cells were grown in a Northern Blot Analysis--
Northern blotting was carried out
using 2 µg of poly(A)+ RNAs isolated from different human
normal tissues, fractionated by denaturing agarose gel electrophoresis
and transferred onto charged nylon membranes (Origene Technologies).
The blots were hybridized to a TOPK probe of 1030-base pair PCR product
by N2H1recF1-BamHI and N2H1recB1-EcoRI primers,
as described previously; the product was labeled using a Megaprime kit
(Amersham Pharmacia Biotech) and [ RT-PCR Analysis--
For the analysis of mRNA expression in
cells and tissues, reverse transcription (RT)-PCR analysis was also
carried out using a specific primer set of N2H1F1 and N2H1B1. The RNA
of normal tissues was purchased from Sawady Tech. The cDNA was
synthesized using a cDNA synthesis kit (Amersham Pharmacia Biotech)
with 1 µg of each RNA. As a reference for mRNA contents, PCR
using actin primers was carried out. 25 cycles of PCR were performed,
and the products were subjected to agarose gel electrophoretic analysis.
In Vitro Kinase Assay--
Protein kinase activity was estimated
using activated recombinant GST-TOPK fusion protein and
[
An in vitro phosphorylation assay of TOPK protein was also
carried out using gel-bound GST-TOPK and COS-7 lysate with our without
PMA stimulation as described above. [ Western Blotting--
Western blotting was carried out using a
nitrocellulose membrane (Bio-Rad) or polyvinylidene difluoride membrane
(Millipore, Bedford, MA) and an ECL detection system (Amersham
Pharmacia Biotech). Samples were subjected to SDS-PAGE analysis and
transferred to the membrane using a semidry blotter (BioCraft, Tokyo,
Japan) for 60 min at 1 mA/cm2. The membrane was then
submerged in blocking solution consisting of 5% skim milk, PBS, and
0.1% Tween 20 (milk-PBST) for 2-5 h at room temperature. Next, the
membrane was incubated with the first antibody solution diluted in the
PBS, 5% bovine serum albumin, 0.1% Tween 20 (BSA-PBST) for 60 min at
room temperature or overnight at 4 °C and washed three times with
washing buffer consisting of 0.1% Tween 20 and 0.15 M
NaCl. The antibodies used in this study were anti-RGS His-Tag mouse
monoclonal antibody (Quiagen); anti-phospho-p38, phospho-JNK, and
phospho-ERK rabbit polyclonal antibodies (New England BioLabs, Beverly,
MA); and anti-total p38 goat polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA). The membrane was incubated with
horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat
antibody solution (Santa Cruz) in BSA-PBST for 60 min at room
temperature and washed four times with washing buffer. The membrane was
developed using the ECL solution and an x-ray film (Hyper film;
Amersham Pharmacia Biotech) exposure was made.
Ligand Precipitation Study--
The activated form of TOPK-GST
fusion protein bound with glutathione-Sepharose 4B was mixed with COS-7
lysate with or without transfection of pcDNA-p38, using the
"activated" glutathione-Sepharose 4B gel as the control. After
incubation at 4 °C overnight, gels were washed four times with a
lysis buffer of 1% Nonidet P-40, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM EDTA, and the SDS-PAGE sample buffer was
added and incubated at 100 °C for 5 min. Samples were then subjected
to SDS-PAGE and electrotransferred to a polyvinylidene difluoride
membrane. The membrane was blocked by 5% milk-PBST overnight at
4 °C and stained by anti-phospho- and anti-total p38 antibody and
developed by the ECL system described above.
Data Analysis--
Data analysis was carried out by MacVector
software using a Super Mac S900 computer (UMAX, Tokyo, Japan) and by
use of the Internet home page at Genome Net. Alignment analysis was
carried out using an ExPaSy home page.
Molecular Cloning and Structure of TOPK--
The cDNA and its
deduced amino acid sequence of TOPK are shown in Fig.
1. The translational initiating point
should be the second methionine site. The deduced TOPK protein consists
of 322 amino acids. The capping site analysis of mRNA revealed that
two forms of TOPK mRNA exist (Fig.
2), one major form seen in 70% of the
human normal spleen library and the second minor form seen in 30% of
the library. The difference between the two forms is the very beginning
point at the 5'-site, but both mRNAs will encode the same
protein.
BLAST homology analysis of TOPK showed modest similarity with MAPKK
(data not shown). The phylogenetic analysis with human MAPKKs indicated
that it lies between the branches for MEK1/2 and MKK7 (Fig.
3).
A serine/threonine protein kinase motif was found in TOPK. However,
there are some exceptions (Fig. 4); the
GXGXXG pattern seen in the first domain of
typical protein kinases is replaced by GXGXXV in
TOPK; the RDLXXXN pattern in the sixth domain is changed to
GDLXXXN; DFG in the seventh domain is changed to DVG; APE in
the eighth domain is changed to AVE; DXWXXG in
the ninth domain is changed to DXFXXG. In
addition, the first serine/threonine site seen between the seventh and
eighth domains of a MAPKK family member is changed to asparagine in
TOPK, whereas the following serine/threonine site is conserved (Fig.
4).
Expression of TOPK mRNA--
TOPK mRNA expression was
analyzed by a Northern blot analysis using normal human tissues (Fig.
5). The expression of TOPK mRNA was
specific for the testis. There are two bands at 1.9 and 2 kilobase
pairs. Two forms in the cap site analysis may be responsible for these
two bands. RT-PCR analysis of normal tissues showed the same result as
Northern blot analysis (Fig. 6). A
smaller PCR product seen in the placental tissue may be nonspecific;
there was no band in the Northern blot. RT-PCR analysis indicated that mLT+ and mLT2+ LAK cells express a significant
amount of TOPK mRNA, whereas the deactivated form of LAK cells,
i.e. mLT Expression of TOPK Proteins in COS-7 Cells--
The open reading
frame of TOPK cDNA was cloned into pcDNA3 vector with
MRGS-His6-Tag and transfected to COS-7 cells. The molecular mass of
TOPK with MRGS-His6-Tag was 40 kDa, which is slightly higher than
expected from its deduced amino acid sequence of 37,337 (Fig.
7).
In Vitro Protein Kinase Activity of TOPK--
Recombinant GST
fusion protein was established by a cloning of the TOPK gene
into the pGEX-2TK vector and a transformation of BL21(DE3) E. coli cells. After induction by 0.1 mM
isopropyl-1-thio- TOPK Activates p38 MAPK but Not ERK or JNK in Vivo--
To see the
substrate specificity and the MAPKK-like activity of TOPK in
vivo, the TOPK gene was transfected to COS-7 cells and
the expressions of phosphorylated forms of three MAPK, i.e. p38, ERK, and JNK, were examined by Western blot analysis (Fig. 10). TOPK induced phospho-p38 but not
phospho-JNK or phospho-ERK. The total p38 expression in the TOPK and
mock-transfected COS-7 cells were comparable (Fig. 10). To confirm the
p38 phosphorylation, an in vitro kinase assay was carried
out using the activated gel-bound form of TOPK. Activated TOPK
phosphorylated recombinant GST-p38 MAPK prominently (Fig.
11).
Binding of TOPK with p38--
To see substrate specificity, the
binding of TOPK with p38 MAPK was examined in vitro.
Activated GST-TOPK gel was incubated with COS-7 lysate overnight. A
faint total p38 MAPK band was seen where the TOPK gel had been used,
which indicated phosphorylation (Fig.
12). A total p38 band was more evident
when using p38 MAPK-transfected COS-7 lysate than when using native
COS-7 lysate (Fig. 13).
TOPK Phosphorylation by COS-7 Lysate in Vitro--
The
phosphorylation of TOPK protein was examined by an in vitro
kinase assay using GST-TOPK and COS-7 lysate (Fig.
14). TOPK was phosphorylated by COS-7
lysate. PMA-stimulated COS-7 lysate was more potent in the
phosphorylation activity.
We have cloned a novel protein kinase from a T-LAK cell
subtraction library. As shown in this study, this novel kinase, TOPK, appears to be a new member of the MAPKK family that may play an important role in the activation of T-LAK cells. T-LAK cells are mainly
composed of activated T-cells, possessing no evident target specificity
via T-cell receptor (12, 13). However, T-LAK cells share basic
cytotoxic mechanisms against target cells such as the perforin-granzyme
system and tumor necrosis factor/Fas-related cytotoxic functions with
specifically activated T-cells or T-cell clones (13, 20). Hence, the
new MAPKK family member TOPK is presumed to play some important roles
in signaling for the mediation of the cytotoxic functions of T-cells as
well as T-LAK cells.
A BLAST homology search and phylogenetic analysis indicated that TOPK
resembles the dual specific MAPKK. It lies between MEK1/2 and MKK7 in
the tree, closer to MEK1/2 than to MKK7. TOPK phosphorylates p38 but
not JNK or ERK in vivo. Accordingly, TOPK is functionally related with MKK3/6 but not with MKK7 or MEK1/2. MKK7 activates JNK but
not p38 or ERK (5, 21). MEK1/2 phosphorylates ERK1/2 exclusively (22).
TOPK is missing some of the typical amino acid sequence of the MAPKK
family, i.e. (S/T)XXX(S/T) between the seventh
and eighth domain, which is important for the catalytic function (5,
23, 24). Instead, TOPK possesses NXXXT, where the first
serine or threonine is replaced by an asparagine. It is not known
whether the phosphorylation of the second threonine in TOPK is enough
for the catalytic activity of this kinase. Phosphorylation of other
amino acid residues might be necessary. Mutational analysis is under investigation.
TOPK does not have any kinase activity, unless it is activated by some
unidentified kinases (data not shown). We used a "bulk activation
method" to activate the gel-bound recombinant TOPK using
PMA-stimulated COS-7 lysate as the activator source. As shown in this
study, the phosphorylation of TOPK protein was confirmed by this
method. When activated by the cell lysate, TOPK exhibited kinase
activity, which is prominent in p38 phosphorylation. This evidence
supports the idea that TOPK is an MAPKK member that needs a
phosphorylation of the specific amino acid residues for its catalytic activity.
At this moment, the specific activator of TOPK is unknown.
PMA-stimulated COS-7 lysate should contain the activator. Molecular association analysis using recombinant protein or a yeast two-hybrid method will be helpful for the identification of the activator, which
must be identified so that the TOPK signaling cascade can be
understood. We have identified a novel mixed lineage kinase-like kinase
from the T-LAK subtraction library (data not shown), which is under
investigation now.
TOPK was shown to accept p38 as a specific substrate in this study. The
transfection study using the pcDNA3-TOPK construct to COS-7 cells
indicated this. A specific antibody exhibited a phospho-p38 MAPK band
in the TOPK-transfected cell lysate. The target specificity was
confirmed by a precipitation analysis using activated GST-TOPK bound
with Sepharose gel in vitro, where anti-phospho-p38 antibody
demonstrated that the p38 bound with TOPK is phosphorylated. Identification of a scaffolding protein for these two kinases will be
the next step (25, 26).
The tissue distribution of TOPK mRNA expression is unique. In
normal tissues, only the testis expresses TOPK mRNA.
Testis-specific protein kinases have been reported (27-30), and some
spermatogenetic roles of these kinases have been debated; however, the
precise mechanisms of these kinases, such as target specificity and
signaling cascades, remain to be elucidated. On the other hand, TOPK
phosphorylates p38 MAPK, and its signaling can be examined from the
viewpoint of a MAPK cascade in the testis.
TOPK is expressed in the mLT+ and mLT2+ T-LAK
cells. This was confirmed in the mRNA expression and also in the
protein levels of our study (data not shown). TOPK may exclusively
phosphorylate p38 MAPK, which plays important roles in the cell
signaling via surface receptors such as T-cell receptor on T-cells and
CD20 on B-cells (6, 11, 31). This indicates that TOPK may play some
critical roles in T-LAK cells. The elucidation of TOPK signaling in
T-LAK cells and T-cells appears imperative.
This is a beginning study on the novel kinase TOPK, which may be an
important regulator in immune cells. Further molecular and biological
analyses are in progress.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and membrane protein lymphotoxin-
(14, 15), whereas a deactivated form of T-LAK cells is
totally devoid of expression (16, 17). Although similar in their
continuing cytotoxic activities, i.e. short term killing of
cancer cells and maintenance of major phenotypic expressions such as
CD3, CD4, and CD8 on the cell membrane, these two types of T-LAK cells
are strikingly different in their cytolytic activity, i.e.
long term cancer cell killing based on cytokine production (16, 17). We
applied a cDNA subtractive strategy based on a polymerase chain
reaction (PCR) method (18) to these unique counterparts of T-LAK cells
and established a subtraction cDNA fragment library. Many unique
cDNA fragments were found by a random sequencing of this library.
Among them, a consensus fragment possessing a protein kinase motif was
identified and a molecular cloning was carried out. This novel protein
kinase, named TOPK (T-LAK cell-originated protein kinase) was revealed
to be expressed in the activated T-LAK cells, lymphoid tumor cells, and
normal testicular tissue. TOPK is a newly identified member of the MAPK
kinase (MKK)3/6-related MAPKK family that phosphorylates p38 MAPK,
which is believed to be involved in the activation of lymphoid cells
and the maintenance of testicular cell functions.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-galactopyranoside for 2.5 h
after preculturing. E. coli cells were centrifuged to form a
precipitate and were dissolved by a freeze-thaw method followed by a
sharing of genomic DNA using a 20-gauge needle, a syringe, and
sonication in a lysis buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 100 µg/ml lysozyme). The supernatant of cell lysate was applied to the
glutathione-Sepharose 4B column and washed with the lysis buffer
without lysozyme. Recombinant fusion protein was subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) analysis. Recombinant
glutathione S-transferase (GST) fusion protein was eluted
from the glutathione-Sepharose gel using an elution buffer (20 mM Tris-HCl, pH 9.6, 120 mM NaCl, 20 mM glutathione). Protein concentrations were estimated
using a D/C protein assay kit (Bio-Rad, Tokyo, Japan).
= 60-mm
culture dish for 20 h before the experiment. After the cells were
washed with OptiMEM I media (Life Technologies, Inc.), a mixed solution
of 5.0 µg of plasmid and 20 µl of Lipofect AMINE was added to the
cells and incubated for 5 h at 37 °C, 5% CO2. The
medium was changed to 10% Dulbecco's modified Eagle's medium without
antibiotics and cultured overnight, and cells were then harvested for analysis.
-32P]CTP (Amersham
Pharmacia Biotech). Hybridization to the actin probe (Origene
Technologies) was performed as the control.
-32P]ATP (0.11 terabecquerels/mmol, Amersham
Pharmacia Biotech). COS-7 cells (5 × 106 cells) were
incubated with 100 ng/ml phorbol 12-myristate 13-acetate (PMA) in 10%
Dulbecco's modified Eagle's medium for 3 h at 37 °C, 5%
CO2, and cells were lysed with the lysis buffer consisting of 1% Nonidet P-40, 25 mM HEPES, 25 mM
glycerophosphate, 25 mM MgCl2, 2 mM
dithiothreitol, 1 mM EDTA, 0.1 mM
Na3VO4, and 1 mM phenylmethylsulfonyl fluoride and then incubated for 1 h on ice. After centrifugation, COS-7 cell lysate (50% of the final reaction volume) was incubated with recombinant GST-TOPK bound with
glutathione-Sepharose 4B at 30 °C for 30 min with the addition of 20 µM ATP and washed three times with lysis buffer. The
protein concentration of the COS-7 lysate was 1.1 mg/ml estimated by a
D/C protein assay kit (Bio-Rad). For assaying, activated GST-TOPK gel
was washed twice with kinase buffer consisting of 25 mM
HEPES, 25 mM glycerophosphate, 25 mM
MgCl2, 2 mM dithiothreitol, 1 mM
EDTA, and 0.1 mM Na3VO4. Activated
GST-TOPK with or without the addition of dephosphorylated casein (100 µg/ml; Sigma, Tokyo, Japan), myelin basic protein (MBP, 20 µg/ml;
Sigma), or recombinant p38 MAPK-GST fusion protein, at 5 µg/ml
(Upstate Biotechnology, Lake Placid, NY) in the kinase buffer was
incubated at 30 °C for 30 min. The enzymatic reaction was stopped by
the addition of SDS-PAGE sample buffer and subjected to SDS-PAGE
analysis. After electrophoresis, the gel was dried up or
electrotransferred to a nitrocellulose membrane, and an x-ray film
(BioMax; Amersham Pharmacia Biotech) exposure was made.
-32P]ATP was
employed in the assay. After the incubation, samples were subjected to
SDS-PAGE analysis and autoradiography was carried out.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (53K):
[in a new window]
Fig. 1.
Nucleotide and deduced amino acid sequences
of human TOPK cDNA.
![]()
View larger version (9K):
[in a new window]
Fig. 2.
Cap site analysis of TOPK mRNA.
5'-Site of two sequences (Cap1 and Cap2) are shown. Clone#1,
TOPK clone 1 (N2H1#1).

View larger version (7K):
[in a new window]
Fig. 3.
Phylogenetic analysis of human MAPKKs and
TOPK.

View larger version (85K):
[in a new window]
Fig. 4.
Alignment of the amino acid sequences of TOPK
and human MKK3. The kinase subdomain numbers are indicated on the
bottom, and the typical common amino acid residues are shown
on the top. Identical and homologous amino acid residues are
indicated by boxes and shaded areas,
respectively. Asterisks indicate common serine/threonine
sites of the MAPKK family.
LAK cells, does not (Fig. 6). RPMI
1788 B-cell lymphoma cells express TOPK mRNA, whereas WiDr and
HT-29 colon cancer cells show no evident expression of TOPK
mRNA.

View larger version (121K):
[in a new window]
Fig. 5.
Top, Northern blot analysis of TOPK in
various normal human tissues. Size markers are indicated on the
left. The
-actin probe (bottom) was used for
the control. The lanes contain 2 µg of poly(A)+ mRNA
of each tissue. Lanes: 1, brain; 2,
heart; 3, kidney; 4, spleen; 5, liver;
6, colon; 7, lung; 8, small intestine;
9, muscle; 10, stomach; 11, testis;
12, placenta.

View larger version (32K):
[in a new window]
Fig. 6.
Top, RT-PCR analysis of TOPK in various
normal human tissues, T-LAK cells, and human cancer cells. The
arrowhead indicates the expected PCR product size. RT-PCR of
-actin was carried out for the control (bottom).
Lanes: a, brain; b, heart;
c, lung; d, kidney; e, liver;
f, spleen; g, stomach; h, intestine;
i, muscle; j, leukocyte; k, testis;
l, placenta; m, mLT
T-LAK cells;
n, mLT+ T-LAK cells; o,
mLT2+ T-LAK cells; p, WiDr cells; q,
HT-29 cells; r, RPMI 1788 cells.

View larger version (40K):
[in a new window]
Fig. 7.
Expression of TOPK in COS-7 cells. A
pcDNA3-MRGS-His vector with (2) or without
(1) an open reading frame of TOPK cDNA was transfected
to COS-7 cells and analyzed by Western blotting. The
arrowhead indicates a specific band of MRGS-His-tagged
TOPK.
-D-galactopyranoside for 2.5 h, a
TOPK band was evident. GST-TOPK protein was purified using
glutathione-Sepharose 4B gel (Fig. 8).
GST-TOPK was then activated by PMA-stimulated COS-7 cell lysates, as
described under "Experimental Procedures," and the activated
gel-bound form of TOPK protein was employed in the in vitro
substrate kinase assay (Fig. 9). Both
casein and MBP were phosphorylated. The autophosphorylation of TOPK
protein was not evident in this study. In the control "activated"
gel, no substrate phosphorylation band was seen (data not shown).
In vitro substrate phosphorylation was not seen with the use
of either the nonactivated gel-bound form or the nonactivated soluble
form of TOPK (data not shown).

View larger version (27K):
[in a new window]
Fig. 8.
Expression and purification of recombinant
TOPK. The recombinant GST-tagged TOPK was induced into BL21(DE3)
E. coli cells transformed by a pGEX-TOPK vector and purified
as described under "Experimental Procedures." The
arrowhead indicates the GST-TOPK band at 65 kDa.

View larger version (66K):
[in a new window]
Fig. 9.
In vitro kinase assay using recombinant
TOPK. The TOPK-GST fusion protein bound with glutathione gel was
employed for an in vitro kinase assay, as described under
"Experimental Procedures." The arrowheads indicate the
phosphorylated casein (upper) and MBP (lower),
respectively. 1, no substrate; 2,
dephosphorylated casein; 3, MBP.

View larger version (25K):
[in a new window]
Fig. 10.
TOPK-transfected cells and phosphorylated
forms of MAPK. COS-7 cells were transfected with pcDNA3-TOPK
(b) or mock vector (a), and cell lysate was
analyzed by Western blotting using anti-phospho-p38, total p38,
phospho-JNK, and phospho-ERK antibodies.

View larger version (50K):
[in a new window]
Fig. 11.
In vitro kinase activity of recombinant TOPK
against casein (a) and recombinant p38
(b). The activated TOPK-GST fusion protein bound with
glutathione gel was employed for an in vitro kinase assay.
The arrowheads indicate the phosphorylated p38
(upper) and casein (lower), respectively.

View larger version (18K):
[in a new window]
Fig. 12.
Gel precipitation analysis using recombinant
TOPK-gel and COS-7 lysate. Native COS-7 cell lysate was mixed with
activated TOPK gel and analyzed by Western blotting using anti-total
p38 (upper) and phospho-p38 (lower) antibodies,
as described under "Experimental Procedures." a,
glutathione gel; b, TOPK-GST bound with glutathione
gel.

View larger version (36K):
[in a new window]
Fig. 13.
Gel precipitation analysis using recombinant
TOPK-gel and p38-transfected COS-7 lysate. COS-7 cell lysate
transfected with pcDNA3-p38 was mixed with TOPK-gel and analyzed by
Western blotting using anti-total p38 antibody. a,
glutathione gel; b, TOPK-GST bound with glutathione
gel.

View larger version (33K):
[in a new window]
Fig. 14.
In vitro phosphorylation assay of TOPK
protein stimulated by COS-7 lysate. Gel-bound GST-TOPK was
incubated with COS-7 cell lysate with or without PMA stimulation. The
arrowhead indicates recombinant GST-TOPK. 1, no
cell lysate; 2, COS-7 cell lysate; 3,
PMA-stimulated COS-7 lysate.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. H. Ito (Tokyo Institute of Technology) and M. Miyake for their support.
| |
FOOTNOTES |
|---|
* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession numbers AB027249 and AB027250.
To whom correspondence should be addressed. Tel.: 81-89-960-5265;
Fax: 81-89-960-5267; E-mail: yasuhito@m.ehime-u.ac.jp.
Published, JBC Papers in Press, April 25, 2000, DOI 10.1074/jbc.M909629199
| |
ABBREVIATIONS |
|---|
The abbreviations used are: MAPK, mitogen-activated protein kinase; T-LAK, lymphokine-activated killer T-cells; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis; JNK, c-Jun N-terminal kinase; ERK, extracellular signal-regulated kinase; PCR, polymerase chain reaction; TOPK, T-LAK cell-originated protein kinase; mLT, membrane lymphotoxin; GST, glutathione S-transferase; RT, reverse transcription; MBP, myelin basic protein; MKK, MAPK kinase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Tan, P. B. O., and Kim, S. K. (1999) Trends Genet. 15, 145-149 |
| 2. | Murga, C., Fukuhara, S., and Gutkind, J. S. (1999) Trends Endocrinol. Metabol. 10, 122-127 |
| 3. | Kentrup, H., Becker, W, Heukelbach, J., Wilmes, A., Schurmann, A., Huppertz, C., Kainulainen, H., and Joost, H.-G. (1996) J. Biol. Chem. 271, 3488-3495 |
| 4. | Clements, J. L., and Koretzky, G. A. (1999) J. Clin. Invest. 103, 925-929 |
| 5. | Foltz, I. N., Gerl, R. E., Wieler, J. S., Luckach, M., Salmon, R. A., and Schrader, J. W. (1998) J. Biol. Chem. 273, 9344-9351 |
| 6. | Zhang, J., Salojin, K. V., Gao, J. X., Cameron, M. J., Bergerot, I., and Delovitch, T. L. (1999) J. Immunol. 162, 3819-3829 |
| 7. | Koprak, S., Staruch, M. J., and Dumont, F. J. (1999) Cell Immunol. 192, 87-95 |
| 8. | Schafer, P. H., Wang, L., Wadsworth, S. A., Davis, J. E., and Siekierka, J. J. (1999) J. Immunol. 162, 659-668 |
| 9. | Rincon, M., Enslen, H., Raingeaud, J., Recht, M., Zapton, T., Su, M. S., Penix, L. A., Davis, R. J., and Flavell, R. A. (1998) EMBO J. 17, 2817-2829 |
| 10. | Crawley, J. B., Rawlinson, L., Lali, F. V., Page, T. H., Saklatvala, J., and Foxwell, B. M. (1997) J. Biol. Chem. 272, 15023-15027 |
| 11. | Craxton, A., Shu, G., Graves, J. D., Saklatvala, J., Krebs, E. G., and Clark, E. A. (1998) J. Immunol. 161, 3225-3236 |
| 12. | Abe, Y., Horiuchi, A., Osuka, Y., Kimura, S., Granger, G. A., and Gatanaga, T. (1992) Lymphokine Cytokine Res. 11, 115-121 |
| 13. | Abe, Y., Van Eden, M., Gatanaga, M., Wang, F. I., Brightbill, H. D., Granger, G. A., and Gatanaga, T. (1993) Lymphokine Cytokine Res. 12, 279-284 |
| 14. | Browning, J. L., Ngam-ek, A., Lawton, P., DeMarinis, J., Tizard, R., Chow, E. P., Hession, C., O'Brine-Greco, B., Foley, S. F., and Ware, C. F. (1993) Cell 72, 847-856 |
| 15. | Abe, Y., Miyake, M., Horiuchi, A., Kimura, S., and Hitsumoto, Y. (1991) Jpn. J. Cancer Res. 82, 23-26 |
| 16. | Horiuchi, A., Abe, Y., Miyake, M., Kimura, K., Hitsumoto, Y., Takeuchi, N., and Kimura, S. (1994) Clin. Exp. Immunol. 96, 152-157 |
| 17. | Miyake, M., Horiuchi, A., Kimura, K., Abe, Y., Kimura, S., and Hitsumoto, Y. (1992) Eur. J. Immunol. 22, 2147-2152 |
| 18. | Lisitsyn, N., Lisitsyn, N., and Wigler, M. (1993) Science 259, 946-951 |
| 19. | Ohtani, K., Suzuki, Y., Eda, S., Kawai, T., Kase, T., Yamazaki, H., Shimada, T., Keshi, H., Sakai, Y., Fukuoh, A., Sakamoto, T., and Wakamiya, N. (1999) J. Biol. Chem. 274, 13681-13689 |
| 20. | Spitzer, J. H., and Meadows, G. G. (1999) Cell Immunol. 194, 205-212 |
| 21. | Matsuda, S., Moriguchi, T., Koyasu, S., and Nishida, E. (1998) J. Biol. Chem. 273, 12378-12382 |
| 22. | Butch, E. R., and Guan, K.-L. (1996) J. Biol. Chem. 271, 4230-4235 |
| 23. | Moriguchi, T., Kuroyanagi, N., Yamaguchi, K., Gotoh, Y., Irie, K., Kano, T., Shirakabe, K., Muro, Y., Shibuya, H., Matsumoto, K., Nishida, E., and Hagiwara, M. (1996) J. Biol. Chem. 271, 13675-13679 |
| 24. | Stein, B., Brady, H., Yang, M. X., Young, D. B., and Barbosa, M. S. (1996) J. Biol. Chem. 271, 11427-11433 |
| 25. | Scott, J. D. (1999) J. Clin. Invest. 103, 761-766 |
| 26. | Ito, M., Yoshioka, K., Akechi, M., Yamashita, S., Takamatsu, N., Sugiyama, K., Hibi, M., Nakabeppu, Y., Shiba, T., and Yamamoto, K. I. (1999) Mol. Cell. Biol. 19, 7539-7548 |
| 27. | Tseng, T. C., Chen, S. H., Hsu, Y. P., and Tang, T. K. (1998) DNA Cell Biol. 17, 823-833 |
| 28. | Toshima, J., Ohashi, K., Okano, I., Nunoue, K., Kishioka, M., Kuma, K., Miyata, T., Hirai, M., Baba, T., and Mizuno, K. (1995) J. Biol. Chem. 270, 31331-31337 |
| 29. | Kueng, P., Nikolova, Z., Djonov, V., Hemphill, A., Rohrbach, V., Boehlen, D., Zuercher, G., Andres, A. C., and Ziemiecki, A. (1997) J. Cell Biol. 139, 1851-1859 |
| 30. | Becker, W., Kentrup, H., Heukelbach, J., and Joost, H. G. (1996) Biochim. Biophys. Acta 1312, 63-67 |
| 31. | Schafer, P., Wadsworth, S. A., Wang, L., and Siekierka, J. J. (1999) J. Immunol. 162, 7110-7119 |
This article has been cited by other articles:
![]() |
A. Yoda, K. Toyoshima, Y. Watanabe, N. Onishi, Y. Hazaka, Y. Tsukuda, J. Tsukada, T. Kondo, Y. Tanaka, and Y. Minami Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase J. Biol. Chem., July 4, 2008; 283(27): 18969 - 18979. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fadloun, D. Kobi, J.-C. Pointud, A. K. Indra, M. Teletin, C. Bole-Feysot, B. Testoni, R. Mantovani, D. Metzger, G. Mengus, et al. The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis Development, August 15, 2007; 134(16): 2947 - 2958. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-M. Oh, F. Zhu, Y.-Y. Cho, K. W. Lee, B. S. Kang, H.-G. Kim, T. Zykova, A. M. Bode, and Z. Dong T-Lymphokine-Activated Killer Cell-Originated Protein Kinase Functions as a Positive Regulator of c-Jun-NH2-Kinase 1 Signaling and H-Ras-Induced Cell Transformation Cancer Res., June 1, 2007; 67(11): 5186 - 5194. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Lin, J. Friederichs, M. A. Black, J. Mages, R. Rosenberg, P. J. Guilford, V. Phillips, M. Thompson-Fawcett, N. Kasabov, T. Toro, et al. Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer Clin. Cancer Res., January 15, 2007; 13(2): 498 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Zykova, F. Zhu, C. Lu, L. Higgins, Y. Tatsumi, Y. Abe, A. M. Bode, and Z. Dong Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells Clin. Cancer Res., December 1, 2006; 12(23): 6884 - 6893. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-H. Park, M.-L. Lin, T. Nishidate, Y. Nakamura, and T. Katagiri PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer. Cancer Res., September 15, 2006; 66(18): 9186 - 9195. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. J. Kang, A. Seit-Nebi, R. J. Davis, and J. Han Multiple Activation Mechanisms of p38{alpha} Mitogen-activated Protein Kinase J. Biol. Chem., September 8, 2006; 281(36): 26225 - 26234. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Dougherty, A. D. R. Garcia, I. Nakano, M. Livingstone, B. Norris, R. Polakiewicz, E. M. Wexler, M. V. Sofroniew, H. I. Kornblum, and D. H. Geschwind PBK/TOPK, a Proliferating Neural Progenitor-Specific Mitogen-Activated Protein Kinase Kinase J. Neurosci., November 16, 2005; 25(46): 10773 - 10785. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salesse and C. M. Verfaillie BCR/ABL-mediated Increased Expression of Multiple Known and Novel Genes That May Contribute to the Pathogenesis of Chronic Myelogenous Leukemia Mol. Cancer Ther., February 1, 2003; 2(2): 173 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. A. Lim, D. D. Hall, and J. W. Hell Selectivity and Promiscuity of the First and Second PDZ Domains of PSD-95 and Synapse-associated Protein 102 J. Biol. Chem., June 7, 2002; 277(24): 21697 - 21711. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Abe, S. Matsumoto, S. Wei, K. Nezu, A. Miyoshi, K. Kito, N. Ueda, K. Shigemoto, Y. Hitsumoto, J.-i. Nikawa, et al. Cloning and Characterization of a p53-related Protein Kinase Expressed in Interleukin-2-activated Cytotoxic T-cells, Epithelial Tumor Cell Lines, and the Testes J. Biol. Chem., November 16, 2001; 276(47): 44003 - 44011. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||